Dose-Dependent Pharmacokinetics of Clofibric Acid in the Non-human Primate
The pharmacokinetics of clofibric acid (CPIB, the active metabolite of Clofibrate) has been studied in two species of non-human primate after administration by two routes at three dose levels. Plasma CPIB concentrations were determined by HPLC. In both the cynomolgus monkey and the baboon, the systemic availability of orally administered CPIB did not differ significantly from 100%; the rates of bioavailability, however, showed a dose-related trend. At the lowest dose level (15 mg/kg), the plasma concentration-time profile appeared to follow first order kinetics, with an apparent t ½ of 1 h; at dose levels which might be used in toxicity studies (45 and 150 mg/kg) the apparent t ½ was longer, indicating dose-related trends by both routes of administration. The pharmacokinetics of CPIB are therefore non-linear over the dose range considered.
CPIB protein binding was concentration-dependent over the range 50–700 μg/ml. Re-estimation of kinetic parameters in terms of free drug concentration did not remove the non-linearity. It is concluded that the pharmacokinetics of CPIB in the non-human primate are dose-dependent but that the extent of absorption of an oral dose was independent of dose level over the range studied.
Key wordsClofibric acid 2-(4-chlorophenoxy)-2-methylpropanoic acid (CPIB) Clofibrate Clofibride Bioavailability Half-life (t½) Kinetics Plasma Primate Protein binding
Unable to display preview. Download preview PDF.
- Cayen MN (1983) Metabolism and pharmacokinetics of antihyperlipidaemic agents. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 7. Wiley, London, pp 173–227Google Scholar
- Wagner JG (1975) Fundamentals of clinical pharmacokinetics, 1st edn. Drug Intelligence, Hamilton, Ill., pp 247–283Google Scholar
- Waller AR, Chasseaud LF, Taylor T (1984) Bioavailability studies of etofibrate in rhesus monkeys (in press)Google Scholar